Developing gene expression signatures of pathway deregulation in tumors
- PMID: 17041087
- DOI: 10.1158/1535-7163.MCT-06-0340
Developing gene expression signatures of pathway deregulation in tumors
Abstract
Recent advances in our understanding of cancer biology have led to the development of therapies targeting specific signaling pathways. Molecular targeting promises to improve our ability to predict who will respond by assessing the state of these targeted pathways in patients. However, a single pathway can be deregulated by multiple mechanisms, and for some pathways it may be difficult to assess activation state by analyzing a single oncogene or tumor suppressor. Therefore, developing gene expression signatures of pathway activation status using model systems or human tumor samples may enable a more reliable measurement of pathway activity. This review discusses recent advances in the identification of gene expression-based signatures of pathway deregulation and how this information may lead to improved therapeutic response prediction.
Similar articles
-
p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.Cancer Res. 2003 May 15;63(10):2616-23. Cancer Res. 2003. PMID: 12750288
-
Exploiting the p53 pathway for cancer diagnosis and therapy.Br J Cancer. 1999 Jul;80 Suppl 1:1-5. Br J Cancer. 1999. PMID: 10466753 Review. No abstract available.
-
Oncogenic pathway signatures in human cancers as a guide to targeted therapies.Nature. 2006 Jan 19;439(7074):353-7. doi: 10.1038/nature04296. Epub 2005 Nov 6. Nature. 2006. PMID: 16273092
-
Integrating RAS status into prognostic signatures for adenocarcinomas of the lung.Clin Cancer Res. 2015 Mar 15;21(6):1477-86. doi: 10.1158/1078-0432.CCR-14-1749. Epub 2015 Jan 21. Clin Cancer Res. 2015. PMID: 25609067
-
KRAS and BRAF: drug targets and predictive biomarkers.J Pathol. 2011 Jan;223(2):219-29. doi: 10.1002/path.2796. Epub 2010 Oct 28. J Pathol. 2011. PMID: 21125676 Review.
Cited by
-
A new molecular signature method for prediction of driver cancer pathways from transcriptional data.Nucleic Acids Res. 2016 Jun 20;44(11):e110. doi: 10.1093/nar/gkw269. Epub 2016 Apr 20. Nucleic Acids Res. 2016. PMID: 27098033 Free PMC article.
-
Cell-Free DNA-Methylation-Based Methods and Applications in Oncology.Biomolecules. 2020 Dec 15;10(12):1677. doi: 10.3390/biom10121677. Biomolecules. 2020. PMID: 33334040 Free PMC article. Review.
-
Revealing global regulatory perturbations across human cancers.Mol Cell. 2009 Dec 11;36(5):900-11. doi: 10.1016/j.molcel.2009.11.016. Mol Cell. 2009. PMID: 20005852 Free PMC article.
-
The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers.Semin Cell Dev Biol. 2016 Oct;58:108-17. doi: 10.1016/j.semcdb.2016.06.012. Epub 2016 Jun 20. Semin Cell Dev Biol. 2016. PMID: 27338857 Free PMC article. Review.
-
Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility.Mol Cancer. 2009 Aug 3;8:58. doi: 10.1186/1476-4598-8-58. Mol Cancer. 2009. PMID: 19646290 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
